Reinhart Partners LLC. Has $60.61 Million Stake in Encompass Health Co. (NYSE:EHC)

Reinhart Partners LLC. cut its position in Encompass Health Co. (NYSE:EHC - Free Report) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 656,320 shares of the company's stock after selling 16,720 shares during the period. Encompass Health accounts for about 2.3% of Reinhart Partners LLC.'s investment portfolio, making the stock its 18th biggest position. Reinhart Partners LLC. owned 0.65% of Encompass Health worth $60,611,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. CIBC Asset Management Inc increased its stake in shares of Encompass Health by 3.5% in the third quarter. CIBC Asset Management Inc now owns 2,957 shares of the company's stock valued at $286,000 after buying an additional 100 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Encompass Health by 1.3% during the second quarter. Commonwealth Equity Services LLC now owns 9,845 shares of the company's stock worth $845,000 after purchasing an additional 123 shares in the last quarter. V Square Quantitative Management LLC grew its stake in shares of Encompass Health by 53.0% during the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company's stock valued at $39,000 after purchasing an additional 140 shares during the last quarter. Verdence Capital Advisors LLC increased its holdings in shares of Encompass Health by 4.6% in the third quarter. Verdence Capital Advisors LLC now owns 3,670 shares of the company's stock valued at $355,000 after purchasing an additional 160 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC lifted its holdings in Encompass Health by 6.6% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 2,749 shares of the company's stock worth $236,000 after buying an additional 170 shares in the last quarter. 97.25% of the stock is owned by institutional investors.

Encompass Health Price Performance

Encompass Health stock traded up $1.49 during midday trading on Monday, reaching $92.54. The company's stock had a trading volume of 529,122 shares, compared to its average volume of 631,217. The stock has a market cap of $9.32 billion, a PE ratio of 22.35, a price-to-earnings-growth ratio of 1.30 and a beta of 0.89. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88. Encompass Health Co. has a 52 week low of $67.94 and a 52 week high of $104.55. The business has a 50-day moving average price of $98.08 and a 200-day moving average price of $93.83.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Monday, October 28th. The company reported $1.03 EPS for the quarter, beating the consensus estimate of $0.94 by $0.09. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the prior year, the firm earned $0.86 EPS. The firm's revenue was up 11.9% compared to the same quarter last year. On average, sell-side analysts predict that Encompass Health Co. will post 4.29 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be paid a $0.17 dividend. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $0.68 annualized dividend and a dividend yield of 0.73%. Encompass Health's dividend payout ratio is currently 16.43%.

Wall Street Analysts Forecast Growth

EHC has been the topic of several recent research reports. UBS Group lifted their price objective on Encompass Health from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, September 25th. KeyCorp lifted their price objective on Encompass Health from $115.00 to $117.00 and gave the company an "overweight" rating in a report on Tuesday, October 29th. Barclays lifted their price target on shares of Encompass Health from $109.00 to $116.00 and gave the company an "overweight" rating in a research note on Tuesday, October 29th. Royal Bank of Canada raised their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Finally, Truist Financial reiterated a "buy" rating and set a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Nine equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $107.11.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.